The wellness and supplement industry is witnessing a significant surge in interest around peptides, as a U.S. FDA advisory panel is set to review seven popular peptides amidst a growing consumer appetite. Major companies are preparing to potentially capitalize on the changing regulatory landscape, with many Americans advocating for easier access to these compounds. While the market for peptides promises opportunities for innovation and revenue, experts express concerns about misinformation and misuse. The upcoming FDA vote could herald a new multibillion-dollar market in telehealth, promising a potential shift in how peptides are viewed in the realm of longevity and health. As the discussion intensifies, the FDA faces the challenge of distinguishing between scientific evidence and hype regarding the efficacy of these trends.